SPRY neffy Launch Success, Global Approvals; $245M Cash
ARS Pharmaceuticals, Inc. (SPRY) announced the successful commercial launch of neffy® (epinephrine nasal spray) in 2025, achieving over 90% commercial coverage and prescriptions from over 22,500 healthcare providers. neffy also secured global approvals in Europe, China, Japan, Australia, and Canada. The company is advancing its intranasal epinephrine platform with a Phase 2b trial for chronic spontaneous urticaria (CSU), expecting interim data in H2 2026. SPRY ended 2025 with $245 million in cash, cash equivalents, and short-term investments, projected to fund operations through cash-flow breakeven. The company also announced its Annual Meeting of Stockholders for June 24, 2026, to elect directors, ratify auditors, and vote on executive compensation.
Key Highlights
- Successful commercial launch of neffy® (epinephrine nasal spray) in 2025.
- Over 22,500 healthcare providers have prescribed neffy to date.
- Achieved over 90% overall commercial coverage for neffy.
- neffy secured global approvals in Europe, China, Japan, Australia, and Canada.
- Advancing Phase 2b clinical trial for neffy in chronic spontaneous urticaria (CSU).
- Interim data from CSU Phase 2b trial anticipated in H2 2026.
- Ended 2025 with $245 million in cash, cash equivalents, and short-term investments.
- Cash expected to support operations through cash-flow breakeven.
- Annual Meeting of Stockholders scheduled for June 24, 2026.